[Use of rosiglitazone in women with polycystic ovarian syndrome].
The purpose of this study is to explore the clinical, biochemical and hormonal changes due to the use/prescription of rosiglitazone to women with PCOS. The study includes 15 women with PCOS and clinical data on insulin resistance, that were treated with a daily dose of 4 mg rosiglitazone (Avandia) for 3 months. At the beginning and at the end of the study we recorded some clinical indicators such as BMI and WHR, some hormonal indicators such as testosterone, insulin, SHBG and DHEAS, as well as some metabolic indicators such as total cholesterol, triglycerides and HDL-C. We discovered a considerable reduction of 27,1% in insulin and HOMA-IR (29,1%), which indicates an improved insulin resistance. The decrease in testosterone and the increase in SHBG were not statistically significant. However, the lab results allow us to claim that the independent use of rosiglitazone is, in many cases, more appropriate at the beginning of the treatment than the traditionally used conservative methods.